Francis Baumgartner, Constance Baer, Stefanos A Bamopoulos, Edward Ayoub, Marietta Truger, Manja Meggendorfer, Miriam Lenk, Gregor Hoermann, Stephan Hutter, Heiko Müller, Wencke Walter, Martha-Lena Mueller, Niroshan Nadarajah, Piers Blombery, Ulrich Keller, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
The World Health Organization Classification of Hematolymphoid Tumors (WHO) and the International Consensus Classification (ICC) of 2022 introduced major changes to the definition of CMML. To assess qualitative and quantitative implications for patient care, we started with 3,311 established CMML cases (according to WHO 2017 criteria) and included also 2,130 oligomonocytosis cases fulfilling the new CMML diagnostic criteria. Applying both classification systems from 2022, 356 and 241 of oligomonocytosis cases were newly classified as myelodysplastic (MD)-CMML (WHO and ICC 2022, respectively), most of which were diagnosed as MDS according to WHO 2017...
December 8, 2023: Blood